Dr. Danny Oh is a gastroenterologist with more than 20 years of experience spanning clinical care, research, and drug development, including the strategic design and operational execution of multiple inflammatory bowel disease clinical trials.

Dr. Oh has held senior leadership roles across the biotechnology and pharmaceutical industry, most recently serving as Vice President at Denali Therapeutics. Prior to this, he worked at Bristol Myers Squibb on a range of Phase 2-3 gastroenterology trials in IBD, eosinophilic esophagitis, and metabolic dysfunction–associated steatohepatitis. Earlier in his career, Dr. Oh held roles of increasing responsibility at Genentech and Boehringer Ingelheim, contributing to Phase 1–3 programs in IBD and chronic hepatitis B. He began his career in academic medicine as a faculty member at the Medical College of Wisconsin and remains clinically active in the care of patients with IBD.

Dr. Oh earned a BSE in Chemical Engineering from the University of Michigan and an MD from the University of Texas Southwestern Medical School. He completed his training in internal medicine and gastroenterology at Washington University in St. Louis and the University of Pennsylvania.